GR-MD-02

31 stories · following the connections

Business

Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis

By Nasdaq OMXMar 6, 2017, 1:31 PM UTC

Business

Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials

By Nasdaq OMXFeb 7, 2017, 9:40 PM UTC

Business

Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial

By Nasdaq OMXFeb 1, 2017, 1:10 PM UTC

Business

Galectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin Diseases

By Nasdaq OMXNov 10, 2016, 1:00 PM UTC

Business

Galectin Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update

By Nasdaq OMXNov 8, 2016, 1:00 PM UTC

Business

Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference

By Nasdaq OMXAug 31, 2016, 12:00 PM UTC

Business

Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial

By Nasdaq OMXAug 25, 2016, 12:00 PM UTC